Form 4: Heron Therapeutics EVP, CFO Ira Duarte Reports Transaction in Company Stock

Ira Duarte, EVP and CFO of Heron Therapeutics, reports the vesting of restricted stock units and subsequent disposition of shares to cover tax obligations.

Summary

• On April 19, 2024, Ira Duarte, the EVP and Chief Financial Officer of Heron Therapeutics, Inc., reported a transaction involving the company's common stock.
• Mr. Duarte acquired 3,874 shares of common stock through the vesting of restricted stock units.
• Simultaneously, 1,122 shares were disposed of at a price of $2.64 to satisfy tax obligations related to the vesting of the restricted stock units.
• Following these transactions, Mr. Duarte directly owns 87,752 shares of Heron Therapeutics common stock and 58,115 restricted stock units.

Sentiment

Score: 5

Explanation: This is a routine transaction disclosure, and the sentiment is neutral. It reflects standard executive compensation practices.

Positives

• The vesting of restricted stock units indicates that Mr. Duarte is meeting the conditions of his equity compensation plan.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors as they can provide insights into management's views on the company's prospects.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units that vest over time, aligning management's interests with those of shareholders.
• The sale of shares to cover tax obligations upon vesting is a common practice among executives receiving equity compensation.
• Comparable companies such as Pacira BioSciences (PCRX) and Eagle Pharmaceuticals (EGRX) also have executives who regularly file Form 4s related to stock transactions.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it is a routine disclosure of an executive's stock activity.
• Shareholders may view insider transactions as a signal of management's confidence (or lack thereof) in the company, but this particular transaction is primarily related to compensation and tax obligations.

Key Dates